InMed Group

InMed Pharmaceuticals is a clinical-stage biotechnology company specializing in the research, development, and manufacturing of rare cannabinoids and cannabinoid analogs. The company utilizes its proprietary IntegraSyn™ platform, a biosynthetic manufacturing system designed to produce pharmaceutical-grade cannabinoids at a commercial scale. InMed's clinical pipeline is led by INM-755, a topical cannabinol cream that has undergone Phase 2 clinical trials for the treatment of epidermolysis bullosa. The company is also advancing INM-088 for glaucoma and INM-901 for Alzheimer’s disease through preclinical stages. Following the acquisition of BayMedica, InMed has expanded its capabilities to include the supply of rare cannabinoids to the health and wellness industry, diversifying its revenue streams.